Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma

Cancan Luo,1,2 Han Nie,3,4 and Li Yu1,2

1Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
2Institute of Hematology, Nanchang University, Nanchang, China
3Department of Stem Cell Biology, Atomic Bomb Diseases Institute, Nagasaki University, Japan
4Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan

Correspondence should be addressed to Li Yu; iluyuliyl@163.com

Received 28 September 2021; Revised 11 December 2021; Accepted 24 December 2021; Published 13 January 2022

1. Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm in adults, accounting for approximately 30% of non-Hodgkin’s lymphomas (NHLs) diagnosed annually. DLBCL exhibits a striking heterogeneity at the clinical, genetic, and molecular levels [1]. The standard rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP) regimens are the first-line immunochemotherapy regimens for patients with DLBCL; however, 30%-40% of patients remain resistant to R-CHOP and are refractory or experience relapse [2, 3]. The prognosis of DLBCL has been developed from International Prognostic Index (IPI) scores, up to the genetic subtype classification [4]. Considering age, disease stage, serum lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group (ECOG), performance status (PS), and the number of extranodal sites, patients with newly diagnosed DLBCL can be stratified into three different...
risk groups. Furthermore, while recurrent genetic aberrations in individual genes have elucidated oncogenic mechanisms in DLBCL, the progress toward a genetic classification of DLBCL tumours is characterised by genomic aberrations in subtype-specific hallmark genes. The potential clinical utility of this genetic classification is evident from the association of the subtypes with outcomes following R-CHOP therapy [5].

Considering IPI and NCCN-IPI scores, age > 60 years is an adverse prognostic factor for DLBCL. Older patients with DLBCL (≥60 years) are associated with a worse outcome compared to younger patients (<60 years) [6]. Within 2 years after the diagnosis of DLBCL, the standard R-CHOP immunotherapy drugs can normalise the life expectancy of young patients, as exhibited by event-free survival rates; however, elderly patients will still experience high mortality [7]. Moreover, it should be noted that the main age group for DLBCL is among the elderly. The median age at the time of diagnosis is 66 years; furthermore, 20.1% of patients are diagnosed between 75 and 84 years of age, 25.0% between 65 and 74 years of age, and 21.2% between 55 and 64 years of age. At present, effective treatment among the elderly remains challenging owing to the adverse invasive biological characteristics of DLBCL, the baseline health status of this patient population, the late toxicity of chemotherapy, and the poor therapeutic effect of the current treatment scheme on elderly patients [8, 9]. Therefore, interest in the understanding of the molecular and genetic pathways dysregulated in ageing and DLBCL has tremendously increased, along with the interest in biomarkers as a quick and quantitative measure in all areas of biomedical research.

Ageing is a process wherein the adaptability and organ function of all organisms decline over time, eventually leading to death [10]. Ageing is often caused by changes in the genome and cells, including tissue degradation and disintegration caused by loss of stem cell renewal ability, genomic instability, telomere wear, metabolic changes, changes in cell communication, cell ageing, loss of protein homeostasis, and epigenetic changes [11]. Notably, B cell immune weakness is a sign of systemic weakness, and ageing may lead to a sharp decline in B cell diversity with age, which could have an important impact on the immune health of the elderly [12]. Because the incidence of DLBCL is mainly among the elderly and considering that the treatment effect for this patient population is poor, we speculate that DLBCL incidence is related to body ageing and cellular immunity. Therefore, because multiple molecular pathways are involved in the ageing process and can contribute to the various aspects of DLBCL, a panel of valid ageing genes (AGs) in DLBCL and its effect on immune function may allow both diagnosis and follow-up in preclinical and clinical settings.

2. Materials and Methods

2.1. Data Access, Acquisition of AGs, and Setting of Samples. We searched and screened the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) and obtained the gene expression matrix and clinical data of three datasets: GSE10846 (which included tumour specimens and the clinical data of 414 patients with DLBCL from 10 institutions in North America and Europe) [13], GSE11318 (which included tumour specimens and the clinical data of 203 patients with DLBCL from the US National Institutes of Health and the University of Nebraska Medical Center, among others) [14], and GSE32918 (which included tumour specimens and the clinical data of 172 patients with DLBCL from the Yorkshire and Humberside Haematology Network) [15]. We used GSE10846 (included tumour specimens and the clinical data of 414 patients with DLBCL) in the screening of feature genes and as the training set during model construction, whereas GSE11318 and GSE32918 were used as the verification set (details on the original and clinical data of these datasets can be obtained in the cited references). A total of 307 AGs were obtained from HAGR (http://genomics.senesence.info/genes/) [16] (Supplementary Table 1). The expression matrix of the AGs in the training set was extracted and sorted out by using the limma package in R (version 4.0.2).

2.2. Screening and Modelling of Prognosis-Related Ageing Genes. Combined with the overall survival (OS) from the clinical information of the training set, prognosis-related AGs were screened using univariate Cox regression analysis. The “glmnet” package in R (version 4.0.2) was used to analyse the prognosis-related AGs through the least absolute shrinkage and selection operator (LASSO) Cox regression analysis, and a predictive model was constructed. The risk score of the model was determined according to the standardised expression level of each gene and the corresponding regression coefficient. The formula for calculating the risk score was as follows:

\[
\text{Risk score} = \sum_i \ln \text{Coef}(i) \times x(i).
\] (1)

Patients were divided into high- and low-risk groups according to the risk values calculated by the model.

2.3. Verification of the Ageing Gene Prognostic Model. The risk score of the training set samples was scored according to the AG prognostic model. Then, principal component analysis (PCA) was performed according to the risk score. The “survminer” package was used to analyse survival in the training set samples scored by the model and to evaluate the prognosis prediction of the samples. The “timeROC” package was used to analyse the receiver-operating characteristic (ROC) curve of the training set to evaluate the model efficiency. Then, univariate and multivariate Cox analyses of the clinical characteristics of the model were performed according to the clinical characteristics. The AG prognostic model was used to score the risk in the two verification sets, and the survival and ROC curve analyses of the validation set were performed using the “survminer” and “timeROC” packages, respectively, to test the model reliability.

2.4. GO and KEGG Enrichment Analysis. The genes in the AG prognostic model were analysed using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) through the “clusterProfiler4.0” package [17].

2.5. Prediction of Clinical Features and Nomogram Construction Using the Ageing Gene Prognostic Model. The AG prognostic model was used to score and group the patients
Figure 1: Continued.

(a) Partial likelihood deviance vs log(λ).

(b) Coefficients vs log(λ).

| Gene  | (N = 412) Hazard ratio | 95% CI          | p-value |
|-------|------------------------|-----------------|---------|
| PLA U | 0.83                   | (0.71 – 0.97)   | 0.022*  |
| IL7R  | 0.86                   | (0.75 – 0.98)   | 0.024*  |
| MYC   | 1.20                   | (1.00 – 1.45)   | 0.047*  |
| S100B | 0.91                   | (0.81 – 1.01)   | 0.089   |
| IGFBP3| 0.88                   | (0.77 – 1.00)   | 0.053   |
| NR3C1 | 0.40                   | (0.28 – 0.59)   | < 0.001*** |
| PTK2  | 0.78                   | (0.63 – 0.95)   | 0.014*  |
| TBP   | 1.45                   | (0.95 – 2.10)   | 0.087   |
| CLOCK | 1.81                   | (1.27 – 2.58)   | 0.001** |

# Events: 163; Global p-value (log-rank): 2.0623e–23
AIC: 1691.76; Concordance index: 0.75

Figure 1: Continued.
Figure 1: (a) Cross validation for adjusting parameters in the LASSO regression analysis. (b) LASSO regression analysis of the AG prognostic model (each curve represents each prognostic AG included in the construction of the prognostic model). (c) Gene forest map of the AG prediction model. (d) PCA cluster analysis of the training set samples.

Table 1: Risk score of the AGs prediction model.

| ID  | Coef  | HR          | HR.95L       | HR.95H       | P value   |
|-----|-------|-------------|--------------|--------------|-----------|
| PLAU| -0.1877144 | 0.82885141 | 0.70623866  | 0.97275142  | 0.02155043 |
| IL7R| -0.1559483  | 0.85560339 | 0.74739094  | 0.9794836   | 0.02379409 |
| MYC | 0.18640335  | 1.20490817 | 1.00234197  | 1.44841156  | 0.04715864 |
| S100B| -0.0981711 | 0.90649381 | 0.80965196  | 1.01491883  | 0.08855595 |
| IGFBP3| -0.127716  | 0.88010325 | 0.77334383  | 1.00160072  | 0.05290174 |
| NR3C1| -0.9042901  | 0.40482918 | 0.27603495  | 0.59371708  | 3.69E-06   |
| PTK2| -0.2531792  | 0.77632871 | 0.63465837  | 0.94962314  | 0.0137867  |
| TBP | 0.34647524  | 1.41407449 | 0.95060454  | 2.10351051  | 0.08727396 |
| CLOCK| 0.59230219  | 1.80814633 | 1.2671264   | 2.5801634   | 0.00109444 |

Table 2: Genes in prediction model.

| Symbol | Name                                                                 | Gene ID | Uniprot         |
|--------|----------------------------------------------------------------------|---------|-----------------|
| PLAU   | Plasminogen activator, urokinase                                     | 5328    | UROK_HUMAN      |
| IL7R   | Interleukin 7 receptor                                                | 3575    | IL7RA_HUMAN     |
| MYC    | v-myc avian myelocytomatosis viral oncogene homolog                   | 4609    | MYC_HUMAN       |
| S100B  | S100 calcium binding protein B                                       | 6285    | S100B_HUMAN     |
| IGFBP3 | Insulin-like growth factor binding protein 3                         | 3486    | IBP3_HUMAN      |
| NR3C1  | Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | 2908    | GCR_HUMAN       |
| PTK2B  | Protein tyrosine kinase 2 beta                                       | 2185    | FAK2_HUMAN      |
| TAF1   | TAF1 RNA polymerase II, TATA box-binding protein- (TBP-) associated factor, 250 kDa | 6872    | TAF1_HUMAN      |
| CLOCK  | Clock circadian regulator                                            | 9575    | CLOCK_HUMAN     |
Figure 2: Continued.
with DLBCL who have different clinical characteristics (age, treatment, ECOG grade, subtype, gender, and stage) and to test the reliability of the grouping. A nomogram was constructed to predict the prognosis of these patients according to the various clinical characteristics.

2.6. Relationship between the Ageing Gene Prognostic Model and the Tumour Microenvironment. ESTIMATE [18] was used to score the tumour microenvironment (including tumour purity, immune score, stroma score, and ESTIMATE score) of the training set samples. Differences in the microenvironment between the high- and low-risk groups distinguished through the AG prognostic model were analysed, and survival analysis was performed using the survival time.

2.7. Relationship between the Ageing Gene Prognostic Model and the Immune Cell Infiltration and Immune Checkpoint. CIBERSORT [19] was used to score 22 types of immune cell infiltration in the training set samples. The difference in the high- and low-risk groups distinguished through the AG prognostic model was analysed, and survival analysis was performed using the survival time.

2.8. Statistical Analysis. Survival analysis was performed using the “survminer” package. The ROC curve and ROC analysis were completed using the “timeROC” package. The Cox proportional hazard regression model was used for univariate and multivariate analyses. P < 0.05 was considered to have statistical significance, whereas P < 0.01 was significant.

3. Results

3.1. Screening and Modelling of Prognosis-Related Ageing Genes. Supplementary Figure 1 shows the flow chart of the work. We obtained the expression of 296 AGs using the “limma” package to extract the AGs from the training set GSE10847. Moreover, we obtained 118 AGs related to the prognosis of DLBCL (Supplementary Figure 2) using univariate Cox regression analysis combined with the total survival time in the training set. A model of the AGs related to prognosis was constructed using LASSO regression analysis (Figures 1(a) and 1(b)). A predictive model was also constructed using nine AGs: PLAU, IL7R, MYC, S100B, IGFBP3, NR3C1, PTK2, TBP, and CLOCK (Figure 1(c)). The risk score of the AG prediction model is shown in Table 1. The description of the nine model genes is shown in Table 2.

3.2. Verification of the Ageing Gene Prognostic Model. The AG prognostic model was used to score the training set and divide the patients into the high- and low-risk groups. Then, PCA was used to analyse the training set samples, with the results showing that the samples could be well distinguished (Figure 1(d)). The survival and ROC analyses of the high- and low-risk groups in the training set showed that the survival characteristics of the high-risk group were significantly lower than those of the low-risk group (Figures 2(a) and 2(b)). Moreover, the ROC analysis showed that the area under curve (AUC) value of the model for 1, 3, and 5 years was 0.772, 0.792, and 0.79 (Figure 2(c)), respectively, which indicates that the AG prognostic model had high prediction accuracy. The two other DLBCL datasets (GSE11318 and GSE32918) were used as independent validation datasets to verify the performance of the AG prognostic model. Consistent with the results of the training set, the survival characteristics of the high-risk group were significantly lower than those of the low-risk group in both verification sets (Supplementary Figures 3A, 3B, 3D, and 3E). Furthermore, the AUC value of the model in both validation sets was satisfactory (Supplementary Figures 3C and 3F). Univariate and multivariate regression analyses were also performed on
Figure 3: Continued.
the AG prognostic model combined with clinical characteristics. The clinical characteristics of the training set and the heatmaps of the 9 AG expression profiles are shown in Figure 3(a). The univariate and multivariate analyses shown in Figures 3(b) and 3(c) also demonstrate that the model could be used as independent prognostic factors in patients with DLBCL. The clinical features of the verification sets and the heatmaps of the nine AG expression profiles are shown in Supplementary Figures 4A and 4D. Similarly, the univariate and multivariate regression analyses demonstrated that the AG prognostic model could also be used as an independent prognostic factor for patients with DLBCL in both validation sets (Supplementary Figures 4B, 4C, 4E and 4F).

3.3. GO and KEGG Enrichment Analyses. The AG prognostic model genes were analysed through GO and KEGG enrichment analyses. Figures 4(a)–4(f) show that model genes are involved in transcriptional disorders, cell senescence, the PI3K-Akt signal pathway, and the JAK-STAT signal pathway in cancer.

### Table 1: Univariate and Multivariate Analyses of Clinical Characteristics

| Characteristic | Univariate Analysis | Multivariate Analysis |
|---------------|---------------------|-----------------------|
| Gender        | $p < 0.001$         | $p < 0.001$           |
| Age           | $0.997$             | 1.030 (1.017 – 1.043) |
| Stage         | $< 0.001$           | 1.486 (1.251 – 1.766) |
| LDH           | $< 0.001$           | 1.136 (1.091 – 1.184) |
| Riskscore     | $< 0.001$           | 1.228 (1.179 – 1.279) |

3.4. Prediction of Clinical Features and Nomogram Construction Using the Ageing Gene Prognostic Model. We tested the stability of the AG prognostic model, and the results show that the model has high accuracy in distinguishing the prognosis of patients with different clinical characteristics, including age (>65 years, ≤65 years), treatment (CHOP, R-CHOP), ECOG grade (0-2 points, 3-4 points), subtype (ABC, GCB), sex (female, male), and grade (G1-2, G3-4) (Figures 5(a)–5(h) and 6(a)–6(d)). Notably, the IPI (International Prognostic Index) score is currently recognised as a prognostic indicator of lymphoma. It scores patients with DLBCL according to age, sites of involvement, clinical stage, ECOG grade, and LDH. The scores are divided into low (0-1), medium (2-3),
DNA-binding transcription activator activity, RNA polymerase II-specific
Repressing transcription factor binding
E-box binding
Core promoter binding
Transcription factor complex
Pronucleus
Chromatoid body
RNA polymerase III transcription factor complex
Cell adhesion mediated by integrin
Regulation of cell adhesion mediated by integrin
Corticosteroid receptor signaling pathway
Glucocorticoid receptor signaling pathway

Figure 4: Continued.
Counts

- Log10 (p.adjust)

Counts

- Log10 (p.adjust)

Figure 4: Continued.
and high (4-5) risk. However, our model can further distinguish the prognosis of low-, medium-, and high-risk patients (Figures 6(e)–6(g)), suggesting that the AG prognostic model that we constructed has high reliability and accuracy for predicting the prognosis of patients with DLBCL who have different clinical characteristics, and can be combined with the IPI score for more accurate predictions. Combined with the survival analysis, we constructed a nomogram that includes the risk score and other clinicopathological information to predict the survival time of patients in the training set, as shown in Figures 6(h) and 6(i).

3.5. Relationship between the Ageing Gene Prognostic Model and the Tumour Microenvironment. Because the ageing of the body is usually accompanied by the decline of immune function and the GO and KEGG enrichment analyses showed that model genes are involved in immune-related functions and pathways, we used the ESTIMATE algorithm to determine stroma and immune scores and to explore the tumour microenvironment differences between the high- and low-risk groups. Figure 7(a) shows a heatmap of tumour purity, immune score, stroma score, and ESTIMATE score as well as the nine AG expression profiles. Consistent with our initial hypothesis, compared to the low-risk group, the high-risk group had significantly lower immunity, stroma, and ESTIMATE scores. Moreover, the survival analysis also showed that low scores in these three areas predicted a poor prognosis (Figures 7(b)–7(d)). Furthermore, the high-risk group had a high tumour purity score, which also predicted a poor prognosis (Figure 7(e)).

3.6. Relationship between the Ageing Gene Prognostic Model and Immune Cell Infiltration. We used the CIBERSORT algorithm to further analyse the difference in immune cell infiltration between the high- and low-risk groups. Figure 8(a) shows the infiltration of 22 immune cells in the high- and low-risk group. As demonstrated in Figure 8(b), there is a strong negative correlation between macrophage M1 and activated dendritic cells, immature B cells and memory B cells and macrophage M0 and macrophage M2. Figure 8(c) shows that there is an increased expression of immature B cells, resting NK cells, macrophage M2, eosinophils, and neutrophils in the high-risk group, whereas the expression of delta T cells, macrophages M0, dormant dendritic cells, and resting mast cells increased in the low-risk group. High M2 expression in eosinophils, monocytes, and macrophages was associated with poor prognosis (Figures 8(d)–8(f)), whereas high expression of macrophages M0, dormant dendritic cells, and delta T cells was related with good prognosis (Figures 8(g)–8(i)). This finding suggests that AGs affect the immune function of the body and ultimately affect the prognosis of patients with DLBCL by
Figure 5: Continued.
altering the infiltration of eosinophils, M2 macrophages, delta T cells, M0 macrophages, and dormant dendritic cells.

3.7. Relationship between the Ageing Gene Prognostic Model and Immune Checkpoint. Immune checkpoint blockers, which are at the forefront of immunotherapy, are effective in the treatment of many human cancers, especially malignant cancers and chemotherapy-tolerant cancers. Therefore, we analysed the differences in 37 immune checkpoints in DLBCL between the high- and low-risk groups. The results showed that the expression of TNFRSF9, SIGLEC15, PTPRC, PDCD1LG2, LDHA, JAK1, IL23A, ICOS, CD8A, CD86, CD40LG, CD28, and B2M was increased in the low-risk group (Figure 9(a)). The high expression of ICOS, IL23A, SIGLEC15, PTPRC, LDHA, B2M, TNFRSF9, and CD40LG was also associated with a good prognosis (Figures 9(b)–9(g) and 10(a) and 10(b)). Furthermore, the expression of YTHDF1, VTCN1, TNFSF9, TNFSF18, PVR, LGALS9, LDHC, LDHB, LAMA3, IL12A, FGL1, and CD274 was increased in the high-risk group (Figure 9(a)), and the high expression of YTHDF1, IL12A, LGALS9, TNFSF9, and PVR was associated with poor prognosis (Figures 10(c)–10(g)).

4. Discussion

The extreme genetic and phenotypic heterogeneity of DLBCL presents a challenge in terms of subtype classification, prognosis prediction, and precision treatment. Ageing is an unavoidable physiological process at present, and the accompanying high-risk disease probability remains an unchangeable fact. In this study, we constructed and verified a new AG prediction model that can well distinguish between the prognosis of patients with high- and low-risk DLBCL. To the best of our knowledge, this study is the first to predict the prognosis of patients with DLBCL characterised by AGs. In addition, we constructed a prognostic nomogram, which can be used to individually estimate the OS probability in patients with DLBCL, help to improve clinical monitoring, and guide the duration of adjuvant chemotherapy and treatment.

In the present study, we determined that the nine central AGs, namely, PLAU, IL7R, MYC, S100B, IGFBP3, NR3C1, PTK2, TBP, and CLOCK, were risk factors related to the prognosis of patients with DLBCL. These AGs were reportedly associated with the underlying mechanisms to facilitate DLBCL or lymphoblastic leukaemia formation and progression. Among them, only MYC is the star protein in DLBCL. Approximately 20%-30% of patients with DLBCL harbour the MYC rearrangement or translocation, which functions as an independent high-risk factor. MYC is also closely related to BCL2, and most patients with refractory DLBCL will exhibit double-hit lymphoma (MYC-BCL2 rearrangement) or double protein expression lymphoma (MYC-BCL2 high expression). The clinical manifestations of this kind of DLBCL are also more aggressive [20–22]. MYC binds to DHX33 and promotes PLAU transcription by directly binding to their promoters, thus promoting cancer cell migration [23]. IL-7R expression in non-GCB-type lymphoma is also significantly higher compared to that in GCB lymphoma [24]. S100B reportedly interacts with p53 involved in many tumours, and S100B (beta) sterically blocks sites of phosphorylation and acetylation on p53 that are important for transcription activation [25]. High S100B expression in non-GCB-type lymphoma is also significantly higher compared to that in GCB lymphoma [24]. S100B reportedly interacts with p53 involved in many tumours, and S100B (beta) sterically blocks sites of phosphorylation and acetylation on p53 that are important for transcription activation [25]. High S100B expression in antigen-presenting cells is associated with a good prognosis [26]. IGFBP-3 has been proven to play an important role in a variety of tumours. Zhou et al. reported that miR-196b/miR-1290 participates in the antitumour effect of resveratrol by regulating IGFBP3 expression in acute lymphoblastic leukaemia [27]. In in vitro experiments, IGFBP-3 enhancement can induce the apoptosis of breast cancer cells, and the low expression of IGFBP-3 indicates a poor prognosis [28]. In a previous study, high IGFBP-3 expression improved
Figure 6: Continued.
Survival probability $p < 0.001$

IPI–High
- High risk ($n = 17$)
- Low risk ($n = 11$)

Points

Riskscore

Age

Gender
- Male
- Female

Stage
- Stage III
- Stage I
- Stage II

Total points

1-year survival

3-year survival

5-year survival

Figure 6: Continued.
the survival rate of patients with oral squamous cell carcinoma, achieved through NF-κB/IL-6/ROS signalling to promote radiosensitivity [29]. Chan et al. identified the products of NR3C1 as one of the central effectors of the B-lymphoid restriction of glucose and the energy supply, functioning as metabolic gatekeepers by limiting the amount of cellular ATP to levels that are insufficient for malignant transformation [30]. NR3C1 also plays an important role in acute lymphoblastic leukaemia. Studies have confirmed that the deletion of NR3C1 is one of the reasons for the failure of acute lymphoblastic leukaemia induction. In addition, the mutation of NR3C1 may lead to glucocorticoid resistance and lead to treatment failure and recurrence of acute lymphoblastic leukaemia. TBP, a TATA binding protein, is closely related to metabolism. The increased expression of TBP-2 can lead to impaired insulin sensitivity and glucose-induced insulin secretion, as well as β-cell apoptosis, leading to diabetes. Furthermore, a transfection experiment showed that TBP-2 expression induces apoptosis in IL-2-independent ATL cells [31]. TBP can directly interact with MYC and regulate the transcriptional process [32–34]. The biological clock has always been thought to be associated with cancer, as in non-Hodgkin’s lymphoma. Hoffman et al. have shown that the clock circadian regulator gene can affect the susceptibility to non-Hodgkin’s lymphoma by affecting immune regulation, and the overexpression of MYC in U2OS cells (osteosarcoma cells) weakens the clock and in turn promotes cell proliferation [35]. Patients with DLBCL who have high CLOCK expression also show poor overall survival [36].

In our study, the relationship between AG and DLBCL prognosis was initially established, and nine AGs were then used to construct a risk score through the LASSO Cox regression model. This classification breaks DLBCL into two genetic subtypes that exhibit good performance in predicting prognosis both in the training and two validation sets. Compared with patients in the low-risk group, those in the high-risk group typically presented with more aggressive characteristics, advanced stages, and higher mortality (all $P < 0.05$). Furthermore, the ageing risk score exhibited better predictive capability in further distinguishing the low- and high-risk patients as having low, medium, and high risk when the IPI score was considered to predict the prognosis of patients with DLBCL more accurately. It is worth noting that this model was built from large sample datasets and was successfully verified in two small sample datasets, which shows that the performance of this model is very robust and effective.

Results of the GO and KEGG analyses showed that the nine AGs were related to the development of lymph nodes, the process of lymphocyte apoptosis, the regulation of immune cells, and the immune pathway. Ageing is often accompanied by a change in immune function. Therefore, we analysed the relationship between the AG model and
Risk
Tumor purity
ESTIMATE score
Immune score
Stromal score

TBP
MYC
CLOCK
IL7R
S100B
PLAU
IGFBP3
NR3C1
PTK2

(a)

Figure 7: Continued.
Figure 7: Continued.
Figure 7: (a) Heatmap of the tumour microenvironment characteristics in the high- and low-risk groups. (b) Immune score map of the high- and low-risk groups and the Kaplan-Meier survival curve of the high- and low-immune score groups (blue represents the high-immune score group, whereas red represents the low-immune score group). (c) The matrix score map of the high- and low-risk groups and the Kaplan-Meier survival curve of the high- and low-matrix groups (blue represents the high matrix score, and red represents the low matrix score). (d) ESTIMATE score chart of the high- and low-risk groups and the Kaplan-Meier survival curve of high and low ESTIMATE scores (blue represents the high ESTIMATE score, and red represents the low ESTIMATE score). (e) Tumour purity score map of the high- and low-risk groups and the Kaplan-Meier survival curve of the high- and low-tumour purity score groups (blue represents the high tumour purity score, whereas red represents the low tumour purity score).
Figure 8: Continued.
Figure 8: Continued.
Figure 8: Continued.
Figure 8: (a) The proportion of cell infiltration in 22 types of immune cells in the high- and low-risk groups. (b) The correlation diagram of the immune cells. (c) The scores of 22 types of immune cells in the high- and low-risk groups (*P < 0.05, 0.01, **P < 0.001). (d–i) Kaplan-Meier survival curves of eosinophils, monocytes, M2 macrophages, M0 macrophages, dormant dendritic cells, and delta T cells.
Figure 9: Continued.
Figure 9: (a) Box chart of the difference distribution of immune checkpoints between the high- and low-risk groups (*P < 0.05, **P < 0.01, ***P < 0.001). (b–g) Kaplan-Meier survival curves of ICOS, IL23A, SIGLEC15, PTPRC, and LDHA.
Figure 10: Continued.
immune cell infiltration. The high-risk group had significantly lower immune and matrix scores and a significant increase in the number of dormant NK cells, M2 macrophages, and eosinophils, which represented a low survival rate. NK cells play a key role in preventing haematological malignancies; however, they may enter a state of dysfunction, thus limiting antitumour immunity. Studies have shown that NK cells participate in a large number of metabolic-related transcriptional reprogramming, whereas exposure to fatty acid lymphoma can effectively inhibit NK cell response and cell metabolism [37].

TBP is closely related to the metabolism of the body, and the two can interact with each other and affect DLBCL development. Marchesi et al. have confirmed that the M2 macrophage phenotype is associated with adverse outcomes in patients treated with R-CHOP. Eosinophils are more common in haematological tumours, such as non-Hodgkin’s disease and some lymphomas, and may contribute to tumorigenesis and development by promoting angiogenesis and connective tissue formation in adjacent tumours [38–40], which is consistent with our immune cell survival analysis.

The ageing process is inevitably accompanied by changes in the immune system, such as changes in molecular subtypes or expression levels on the surface of immune cells and enhancement or suppression of immune cell function, and these changes may affect the immune monitoring process, including the immune checkpoint [41–43]. At present, immune checkpoint therapy has provided a huge breakthrough for the treatment of lymphomas. Finding reliable predictive biomarkers and potential targets can hence help reduce the side effects of immunosuppressive therapy and expand its applicability to patients with DLBCL. Therefore, we further investigated the relationship between the AG model and the immune checkpoint. The expression of TNFSF9, CD274, and PVR increased in the high-risk group of the AG model. Moreover, the blockers of CD274 (PD-L1) have been widely tested in patients with a variety of lymphomas, and the blockers of PD-L1, nivolumab, and pembrolizumab have been proven effective for the treatment of recurrent or refractory lymphomas [44]. Furthermore, repeated deletions of TNFSF9 have been detected in patients with DLBCL and Burkett’s lymphoma [45]. PVR is a member of the laminin-like family, which not only promotes tumour progression and metastasis but also involves immunomodulation. It is also highly upregulated in the tumour cells of many cancer types and is associated with poor prognosis. In addition, the current PVR immune checkpoint inhibitors have been supported by a large number of experiments in preclinical cancer models, including colon cancer, liver cancer, and melanoma, with satisfactory results [46–50]. Our immune checkpoint survival analysis also showed that the high expression of TNFSF9 and PVR was associated with poor prognosis.

Although our study provides new ideas and potential therapeutic targets for the study of the pathogenesis of DLBCL. However, this study has some limitations. This is a retrospective study; therefore, designing a prospective study or obtaining clinical samples and evaluating them with Western blot or immunohistochemistry will be more convincing.

5. Conclusion

In conclusion, our study constructed an AG model that can predict the prognosis of patients with DLBCL who have different clinical features. We provide an ageing genetic framework from which to understand its pronounced genetic and clinical heterogeneity as well as the therapeutic responses in subsets of DLBCL tumours defined by shared pathogenesis. This classification breaks DLBCL into two genetic subtypes that differ with respect to gene expression phenotype, oncogenic pathway engagement, tumour microenvironment, and survival rates. In addition, we also explored the relationship between the AG and immune checkpoints in DLBCL and screened out potential immune checkpoints for treatment. This taxonomy provides a roadmap for the prediction and understanding of AGs involving the biological diversity encompassed within

Figure 10: (a–g) Kaplan-Meier survival curves of B2M, TNFRSF9, CD40LG, YTHDF1, IL12A, LGALS9, TNFSF9, and PVR.

\[ p = 0.024 \]
the pathological mechanisms of the disease and will likely shed light on the heterogeneous responses of DLBCL to cytotoxic and molecular-targeted therapies.

**Abbreviations**

AG: Aging-related genes  
GO: Gene Ontology enrichment  
KEGG: Kyoto Encyclopedia of Gene and Genome  
DLBCL: Diffuse large B cell lymphoma  
NHLs: Non-Hodgkin’s lymphomas  
R-CHOP: Rituximab, cyclophosphamide, Adriamycin, vin-cristine, prednisone  
LDH: Lactate dehydrogenase  
ECOG: Eastern Cooperative Oncology Group  
IPI: International Prognostic Index  
OS: Survival time  
PCA: Principal component analysis  
ROC: Receiver operating characteristic  
AUC: Area under curve  
TBP: TATA-binding protein.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Ethical Approval**

This article does not contain any studies with patients or animals performed by any of the authors.

**Conflicts of Interest**

There are no conflicts of interest in this study.

**Authors’ Contributions**

Cancan Luo is responsible for the drafting the manuscript; Han Nie for the research design and helping to draft the manuscript; and Li Yu for the review and revision of the manuscript and writing guidance. Cancan Luo and Han Nie are the co-first authors of this article; Cancan Luo is the 1st of the first authors; HAN NIE is the 2nd of the first authors.

**Supplementary Materials**

**Supplementary 1.** Supplementary Figure 1: the flow chart for analyzing AG prognostic model in DLBCL.

**Supplementary 2.** Supplementary Figure 2: univariate Cox analysis of AGs related to the survival time of patients with DLBCL.

**Supplementary 3.** Supplementary Figure 3: (a) the model divides the patients from the validation set (GSE11318) into the high- and low-risk groups, and the number of survivals and deaths were compared between these groups. (b) The Kaplan-Meier curve for the validation set (GSE11318) divided into the high- and low-risk groups. (c) The receiver operating curve of the model in the validation set (GSE11318). (d) The model divides the patients in the validation set (GSE32918) into the high and low-risk groups, and the number of survivals and deaths were compared between these groups. (e) The Kaplan-Meier curve of the validation set (GSE32918) divided between the high- and low-risk groups. (f) The receiver-operating curve of the model in the validation set (GSE32918).

**Supplementary 4.** Supplementary Figure 4: (a) heatmap of the clinical characteristics of the high- and low-risk groups in the validation set (GSE11318). (b) Univariate analysis of the clinical features in the validation set (GSE11318). (c) Multivariate analysis of the clinical features in the validation set (GSE11318). (d) Heatmap of clinical characteristics of the high- and low-risk groups in the validation set (GSE32918). (e) Univariate analysis of the clinical features in the validation set (GSE32918). (f) Multivariate analysis of the clinical features in the validation set (GSE32918).

**Supplementary 5.** Supplementary Table 1: three hundred nine genes related to aging.

**References**

[1] R. Lang and M. J. Gill, “Diffuse large B-cell lymphoma,” *The New England Journal of Medicine*, vol. 384, no. 23, pp. 2261-2262, 2021.

[2] P. J. Lugtenburg, P. de Nully Brown, B. van der Holt et al., “Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase III trial of the HOVON and the Nordic Lymphoma Group (HOVON-84),” *Journal of Clinical Oncology*, vol. 38, no. 29, pp. 3377–3387, 2020.

[3] R. Vaidya and T. E. Witzig, “Prognostic factors for diffuse large B-cell lymphoma in the R(X) CHOP era,” *Annals of Oncology*, vol. 25, no. 11, pp. 2124–2133, 2014.

[4] J. C. Wight, G. Chong, A. P. Grigg, and E. A. Hawkes, “Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI,” *Blood Reviews*, vol. 32, no. 5, pp. 400–415, 2018.

[5] J. L. Crombie and P. Armand, “Diffuse large B-cell lymphoma’s new genomics: the bridge and the chasm,” *Journal of Clinical Oncology*, vol. 38, no. 30, pp. 3565–3574, 2020.

[6] C. Thieblemont and B. Coifier, “Lymphoma in older patients,” *Journal of Clinical Oncology*, vol. 25, no. 14, pp. 1916–1923, 2007.

[7] L. H. Jakobsen, M. Bøgsted, P. . . N. Brown et al., “Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study,” *Journal of Clinical Oncology*, vol. 35, no. 7, pp. 778–784, 2017.

[8] R. Cordoba, S. Luminari, and T. A. Eyre, “The use of frailty assessments in treating older adults with aggressive lymphomas,” *British Journal of Haematology*, vol. 194, no. 4, pp. 677–685, 2021.

[9] M. Di, S. F. Huntington, and A. J. Olszewski, “Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients,” *The Oncologist*, vol. 26, no. 2, pp. 120–132, 2021.
Oxidative Medicine and Cellular Longevity

[10] B. K. Kennedy, S. L. Berger, A. Brunet et al., “Geroscience: Linking Aging to Chronic Disease,” Cell, vol. 159, no. 4, pp. 709–713, 2014.

[11] C. López-Ortín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “The Hallmarks of Aging,” Cell, vol. 153, no. 6, pp. 1194–1217, 2013.

[12] K. L. Gibson, Y. C. Wu, Y. Barnett et al., “B-cell diversity decreases in old age and is correlated with poor health status,” Aging Cell, vol. 8, no. 1, pp. 18–25, 2009.

[13] G. Lenz, G. W. Wright, N. C. T. Emre et al., “Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 36, pp. 13520–13525, 2008.

[14] S. L. Barrans, S. Crouch, M. A. Care et al., “Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome,” British Journal of Haematology, vol. 159, no. 4, pp. 441–453, 2012.

[15] R. Tacutu, D. Thornton, E. Johnson et al., “Human ageing genomic resources: new and updated databases,” Nucleic Acids Research, vol. 46, no. D1, pp. D1083–D1090, 2018.

[16] T. Wu, E. Hu, S. Xu et al., “Clusterprofiler 4.0: a universal enrichment tool for interpreting omics data,” The Innovations, vol. 2, no. 3, p. 100141, 2021.

[17] K. Yoshihara, M. Shahmoradgoli, E. Martinez et al., “Inferring tumour purity and stromal and immune cell admixture from expression data,” vol. 4, no. 1, p. 2612, 2013.

[18] A. M. Newman, C. L. Liu, M. R. Green et al., “Robust enumeration of cell subsets from tissue expression profiles,” Nature Methods, vol. 12, no. 5, pp. 453–457, 2015.

[19] A. Rosenwald, S. Bens, R. Advani et al., “Prognostic significance of MYC Rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lymphnode Lymphoma biomarker consortium,” Journal of Clinical Oncology, vol. 37, no. 35, pp. 3359–3368, 2019.

[20] D. W. Scott, R. L. King, A. M. Staiger et al., “High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology,” Blood, vol. 131, no. 18, pp. 2060–2064, 2018.

[21] B. Coiffier and C. Sarkozy, “Diffuse large B-cell lymphoma: R-CHOP failure—what to do?,” Hematology: American Society of Hematology Education Program, vol. 2016, no. 1, pp. 366–378, 2016.

[22] J. Fu, Y. Liu, X. Wang, B. Yuan, and Y. Zhang, “Role of DHX33 in c-Myc-induced cancers,” Carcinogenesis, vol. 38, no. 6, pp. 649–660, 2017.

[23] Y. Zhao, W. L. Cui, Z. Y. Feng, J. Xue, A. Gulinier, and W. Zhang, “Expression of Foxp3 and interleukin-7 receptor and clinicopathological characteristics of patients with diffuse large B-cell lymphoma,” Oncology Letters, vol. 19, no. 4, pp. 2755–2764, 2020.

[24] J. van Dieck, D. P. Teufel, A. M. Jaulet et al., “Posttranslational Modifications Affect the Interaction of S100 Proteins with Tumor Suppressor p53,” Journal of Molecular Biology, vol. 394, no. 5, pp. 922–930, 2009.

[25] W. J. Chan, “Pathogenesis of diffuse large B cell lymphoma,” International Journal of Hematology, vol. 92, no. 2, pp. 219–230, 2010.

[26] W. Zhou, S. Wang, Y. Ying, R. Zhou, and P. Mao, “miR-196b/miR-1290 participate in the antitumor effect of resveratrol via regulation of IGFBP3 expression in acute lymphoblastic leukemia,” Oncology Reports, vol. 37, no. 2, pp. 1075–1083, 2017.

[27] H. A. Zieleniszka, C. S. Daly, A. Alghamdi et al., “Interaction between GRP78 and IGFBP-3 affects tumourigenesis and prognosis in breast cancer Patients,” Cancers (Basel), vol. 12, no. 12, pp. 3821, 2020.

[28] S. H. Wang, Y. L. Chen, J. R. Hsiao et al., “Insulin-like growth factor binding protein 3 promotes radiosensitivity of oral squamous cell carcinoma cells via positive feedback on NF-kB/IL-6/ROS signaling,” Journal of Experimental & Clinical Cancer Research, vol. 40, no. 1, p. 95, 2021.

[29] L. N. Chan, Z. Chen, D. Braas et al., “Metabolic gatekeeper function of B-lymphoid transcription factors,” Nature, vol. 542, pp. 7642, 479–483, 2017.

[30] Z. Chen, D. A. Lopez-Ramos, E. Yoshihara et al., “Thioredoxin-binding protein-2 (TBP-2/VDU1/TXNIP) regulates T-cell sensitivity to glucocorticoid during HTLV-I-induced transformation,” Leukemia, vol. 25, no. 3, pp. 440–448, 2011.

[31] H. Masutani, E. Yoshihara, S. Masaki, Z. Chen, and J. Yodoi, “Thioredoxin binding protein (TBP)-2/Txnip and α-arrestin proteins in cancer and diabetes mellitus,” Journal of Clinical Biochemistry and Nutrition, vol. 50, no. 1, pp. 23–34, 2012.

[32] J. R. Ribeiro, L. A. Lovasco, B. C. Vanderhyden, and R. N. Frei, “Targeting TBP-associated factors in ovarian cancer,” Frontiers in Oncology, vol. 4, p. 45, 2014.

[33] Y. Wei, D. Resecca, Z. Li et al., “Multiple direct interactions of TBPI with the MYC oncoprotein,” Nature Structural & Molecular Biology, vol. 26, no. 11, pp. 1035–1043, 2019.

[34] A. E. Hoffman, T. Zheng, R. G. Stevens et al., “Clock-cancer connection in non-Hodgkin’s lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2,” Cancer Research, vol. 69, no. 8, pp. 3605–3613, 2009.

[35] X. Tan, F. Cao, F. Tang et al., “Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration,” Journal of Immunology Research, vol. 2021, Article ID 9995869, 13 pages, 2021.

[36] T. Kobayashi, Y. P. Lam, H. Jiang et al., “Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment,” Blood, vol. 136, no. 26, pp. 3004–3017, 2020.

[37] F. Marchesi, M. Cirillo, A. Bianchi et al., “High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma,” Hematological Oncology, vol. 33, no. 2, pp. 110–112, 2015.

[38] M. Samoszuk, “Eosinophils and human cancer,” Histology and Histopathology, vol. 12, no. 3, pp. 807–812, 1997.

[39] S. Sakkal, S. Miller, V. Apostolopoulos, and K. Nurgali, “Eosinophils in cancer: favourable or Unfavourable?,” Current Medicinal Chemistry, vol. 23, no. 7, pp. 650–666, 2016.

[40] J. Lian, Y. Yue, W. Yu, and Y. Zhang, “Immunosenescence: a key player in cancer development,” Journal of Hematology & Oncology, vol. 13, no. 1, p. 151, 2020.
[42] R. Elias, T. Karantanos, E. Sira, and K. L. Hartshorn, “Immu-
notherapy comes of age: Immune aging & checkpoint inhibi-
tors,” Journal of Geriatric Oncology, vol. 8, no. 3, pp. 229–
235, 2017.

[43] N. D. Johnson and K. N. Conneely, “The role of DNA methyl-
lation and hydroxymethylation in immunosenescence,” Ageing
Research Reviews, vol. 51, pp. 11–23, 2019.

[44] W. Xie, L. J. Medeiros, S. Li, C. C. Yin, J. D. Khoury, and J. Xu,
“PD-1/PD-L1 pathway and its blockade in patients with classic
Hodgkin lymphoma and non-Hodgkin large-cell lympho-
mas,” Current Hematologic Malignancy Reports, vol. 15,
no. 4, pp. 372–381, 2020.

[45] R. Scholtysik et al., “Recurrent deletions of the TNFSF7 and
TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt
lymphomas,” International Journal of Cancer, vol. 131, no. 5,
pp. E830–E835, 2012.

[46] J. S. O'Donnell, J. Madore, X. Y. Li, and M. J. Smyth, “Tumor
intrinsic and extrinsic immune functions of CD155,” Seminars
in Cancer Biology, vol. 65, pp. 189–196, 2020.

[47] P. Kučan Brlić, T. Lenac Roviš, G. Cinamon, P. Tsukerman,
O. Mandelboim, and S. Jonjić, “Targeting PVR (CD155) and
its receptors in anti-tumor therapy,” Cellular & Molecular
Immunology, vol. 16, no. 1, pp. 40–52, 2019.

[48] D. K. Chiu, V. W. H. Yuen, J. W. S. Cheu et al., “Hepatocellular
Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and
Inhibiting the Cytotoxic T-Cell Response via TIGIT to Medi-
ate Tumor Resistance to PD1 Inhibitors in Mice,” Gastroenter-
ology, vol. 159, no. 2, pp. 609–623, 2020.

[49] R. J. Johnston, L. Comps-Agrar, J. Hackney et al., “The Immu-
noreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T
Cell Effector Function,” Cancer Cell, vol. 26, no. 6, pp. 923–
937, 2014.

[50] J. M. Chauvin, O. Pagliano, J. Fourcade et al., “TIGIT and PD-
1 impair tumor antigen-specific CD8+ T cells in melanoma
patients,” The Journal of Clinical Investigation, vol. 125,
no. 5, pp. 2046–2058, 2015.